Baidu
map

JACC:肌联蛋白截断的扩张型心肌病的预后研究

2017-10-26 MedSci MedSci原创

目前,对由肌联蛋白截断(TTNtv)所致的扩张型心肌病(DCM)的心脏表型和预后的理解尚未阐明。本次前瞻性观察性队列研究对DCM患者进行了临床评估、心脏磁共振增加检查和TTN测序,并双盲随访,主要终点复合事件是心源性死亡、心律失常和心衰。最终,本研究共纳入716名DCM患者(平均年龄为53.5 ± 14.3岁,男性占65.5%,80.6%患者的纽约心功能评级为I/II),83 (11.6%)名患者

目前,对由肌联蛋白截断(TTNtv)所致的扩张型心肌病(DCM)的心脏表型和预后的理解尚未阐明。

本次前瞻性观察性队列研究对DCM患者进行了临床评估、心脏磁共振增加检查和TTN测序,并双盲随访,主要终点复合事件是心源性死亡、心律失常和心衰。最终,本研究共纳入716名DCM患者(平均年龄为53.5 ± 14.3岁,男性占65.5%,80.6%患者的纽约心功能评级为I/II),83 (11.6%)名患者为TTNtv,TTNtv患者在入组的时候年龄更小(49.0岁 vs. 54.1 岁; p = 0.002),左室质量指数更低(减少5.1 g/m2; p = 0.03),双心室射血分数无明显差异。经过平均3.9年时间的随访,604名患者中有78名(12.9%)患者出现主要复合终点事件,包括9例TTNtv患者(12.7%)和69例非TTNtv患者(12.9%),两组患者的心源性死亡率、心律失常和心衰的发生风险无明显差异(HR:: 0.92 [95% Cl: 0.45 - 1.87]; p = 0.82)。

研究结果显示,影响DCM的预后因素与影响肌联蛋白截断所致DCM的预后因素无明显差异,两者的预后结局也无明显差异。


原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853824, encodeId=366518538246c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 12 00:47:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636074, encodeId=95ca16360e482, content=<a href='/topic/show?id=ac168096935' target=_blank style='color:#2F92EE;'>#肌联蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80969, encryptionId=ac168096935, topicName=肌联蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=465c22580188, createdName=ms4964546379600229, createdTime=Sun Apr 15 13:47:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684709, encodeId=1eaf1684e0927, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Wed Jan 03 01:47:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325579, encodeId=2f7013255e9ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622286, encodeId=b3e0162228645, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256101, encodeId=c3a4256101dc, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Oct 26 11:18:10 CST 2017, time=2017-10-26, status=1, ipAttribution=)]
    2018-01-12 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853824, encodeId=366518538246c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 12 00:47:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636074, encodeId=95ca16360e482, content=<a href='/topic/show?id=ac168096935' target=_blank style='color:#2F92EE;'>#肌联蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80969, encryptionId=ac168096935, topicName=肌联蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=465c22580188, createdName=ms4964546379600229, createdTime=Sun Apr 15 13:47:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684709, encodeId=1eaf1684e0927, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Wed Jan 03 01:47:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325579, encodeId=2f7013255e9ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622286, encodeId=b3e0162228645, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256101, encodeId=c3a4256101dc, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Oct 26 11:18:10 CST 2017, time=2017-10-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853824, encodeId=366518538246c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 12 00:47:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636074, encodeId=95ca16360e482, content=<a href='/topic/show?id=ac168096935' target=_blank style='color:#2F92EE;'>#肌联蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80969, encryptionId=ac168096935, topicName=肌联蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=465c22580188, createdName=ms4964546379600229, createdTime=Sun Apr 15 13:47:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684709, encodeId=1eaf1684e0927, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Wed Jan 03 01:47:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325579, encodeId=2f7013255e9ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622286, encodeId=b3e0162228645, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256101, encodeId=c3a4256101dc, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Oct 26 11:18:10 CST 2017, time=2017-10-26, status=1, ipAttribution=)]
    2018-01-03 lsj637
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853824, encodeId=366518538246c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 12 00:47:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636074, encodeId=95ca16360e482, content=<a href='/topic/show?id=ac168096935' target=_blank style='color:#2F92EE;'>#肌联蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80969, encryptionId=ac168096935, topicName=肌联蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=465c22580188, createdName=ms4964546379600229, createdTime=Sun Apr 15 13:47:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684709, encodeId=1eaf1684e0927, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Wed Jan 03 01:47:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325579, encodeId=2f7013255e9ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622286, encodeId=b3e0162228645, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256101, encodeId=c3a4256101dc, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Oct 26 11:18:10 CST 2017, time=2017-10-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853824, encodeId=366518538246c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 12 00:47:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636074, encodeId=95ca16360e482, content=<a href='/topic/show?id=ac168096935' target=_blank style='color:#2F92EE;'>#肌联蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80969, encryptionId=ac168096935, topicName=肌联蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=465c22580188, createdName=ms4964546379600229, createdTime=Sun Apr 15 13:47:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684709, encodeId=1eaf1684e0927, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Wed Jan 03 01:47:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325579, encodeId=2f7013255e9ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622286, encodeId=b3e0162228645, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256101, encodeId=c3a4256101dc, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Oct 26 11:18:10 CST 2017, time=2017-10-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1853824, encodeId=366518538246c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jan 12 00:47:00 CST 2018, time=2018-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636074, encodeId=95ca16360e482, content=<a href='/topic/show?id=ac168096935' target=_blank style='color:#2F92EE;'>#肌联蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80969, encryptionId=ac168096935, topicName=肌联蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=465c22580188, createdName=ms4964546379600229, createdTime=Sun Apr 15 13:47:00 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684709, encodeId=1eaf1684e0927, content=<a href='/topic/show?id=794754e74f4' target=_blank style='color:#2F92EE;'>#扩张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54774, encryptionId=794754e74f4, topicName=扩张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=699d28086811, createdName=lsj637, createdTime=Wed Jan 03 01:47:00 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325579, encodeId=2f7013255e9ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622286, encodeId=b3e0162228645, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sat Oct 28 01:47:00 CST 2017, time=2017-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256101, encodeId=c3a4256101dc, content=谢谢分享谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Thu Oct 26 11:18:10 CST 2017, time=2017-10-26, status=1, ipAttribution=)]
    2017-10-26 明天会更好!

    谢谢分享谢谢分享

    0

相关资讯

JACC:PCI术后伴复杂病变解剖结构患者的预后研究

接受长期的双联抗血小板治疗的冠脉支架植入伴复杂病变解剖患者的风险和利益尚未阐明。本研究的目的旨在比较和评估冠脉介入治疗(PCI)后接受30个月和12个月双联抗血小板治疗(DAPT)伴或不伴复杂病变解剖效果的研究。本研究对25416名登记的患者和11554名随机的研究对象的心梗、支架血栓和中到重度出血事件的发现风险进行分析评估。复杂的病变解剖包括以下:无保护左主干病变,> 2 病变/血管,长度

JACC:任何可检测的超敏肌钙蛋白水平都与胸痛患者不良预后相关

目前,对于超敏肌钙蛋白(hs-cTn)水平和胸痛但不伴有心梗患者结局的临床研究鲜有报道。本研究提出一个假设:任何可检测到的高水平hs-cTn均与患者的不良结局预后有关。本研究纳入了2011年至2014年22589名胸痛且大于25岁并检测了hs-cTn水平的患者,将出现有可能影响hs-cTn水平的急性情况患者、心梗患者或缺乏能保证hs-cTn水平稳定信息的患者被排除在外,主要观察的事件为全因死亡率、

Free Radic Biol Med:研究揭示多酚类化合物具有保护心血管作用的原因

相关大群体人口研究显示,摄入含多酚类化合物(如黄酮类)的水果和蔬菜对心血管健康具有益处。

JACC:高效抗逆转录病毒疗法对HIV患儿心脏的保护作用研究

在高效抗逆转录病毒疗法(HAART)问世前,心源性死亡和心血管疾病在HIV患儿中是普遍的。本研究的目的旨在评估HAART对HIV患儿远期心血管保护的有效性。本研究(CHAART-2)比较评估了74名接受HAART的HIV患儿的148个超声心动图与140名没有接受HAART但有HIV患儿的860个超声心动图,并通过广义估计方程评价HAART暴露与超声心动图测量之间的关联。分析结果发现,相比于没有接受

Kidney int:慢性肾脏疾病与心血管死亡风险的相关性研究!

在实验性尿毒症中的研究发现了微血管稀少的现象,但是,关于慢性肾脏病(CKD)患者的相关研究数据十分有限。基于此,近期,一项发表在杂志Kidney int上的研究量化了在单个机构的心肌灌注正电子发射断层扫描的绝对心肌血流量和冠状动脉血流储备情况(峰值与静息流量的比率)。研究者们根据估计的肾小球滤过率,将受试个体分为标准CKD类别。在心血管危险因素调整模型中分析了冠状动脉血流储备与CKD分期和心血管死

JACC:TCS设备在心脏移植患儿中的运用

体外膜式氧合(ECMO)是儿童短期机械循环支持的标准治疗手段,然而,新一代的临时循环支持(TCS)设备相比于ECMO对儿童循环支持的有效性如何尚属未知。本研究目的旨在比较评估TCS较于ECMO对桥接心脏移植存活患儿的有效性是否更佳。本研究纳入了2011年至2015年所有接受心脏移植且接受TCS或ECMO设备循环支持的小于21岁的患儿。接受TCS设备循环支持的患儿与倾向评分配对的接受ECMO设备循环

Baidu
map
Baidu
map
Baidu
map